48,706
edits
Difference between revisions of "Steatosis"
Jump to navigation
Jump to search
tweak
(tweak) |
|||
| Line 3: | Line 3: | ||
| Image = Non-alcoholic fatty liver disease1.jpg | | Image = Non-alcoholic fatty liver disease1.jpg | ||
| Width = | | Width = | ||
| Caption = Steatosis. Elastic [[Masson's trichrome]]. | | Caption = Steatosis. Elastic [[Masson's trichrome stain]]. | ||
| Synonyms = fatty liver | | Synonyms = fatty liver | ||
| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]] | | Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]] | ||
| Line 62: | Line 62: | ||
*Hepatitis D. | *Hepatitis D. | ||
*Weird stuff: | *Weird stuff: | ||
**Congenital defects of fatty acid beta oxidation | **Congenital defects of fatty acid beta oxidation. | ||
**Cholesterol ester storage disease | **Cholesterol ester storage disease. | ||
**Wolman disease and Alpers syndrome. | **Wolman disease and Alpers syndrome. | ||
| Line 77: | Line 77: | ||
Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/> | Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/> | ||
*[[Diabetes mellitus]]. | *[[Diabetes mellitus]]. | ||
*Obesity, non-alcoholic steatohepatitis (NASH). | *[[Obesity]], non-alcoholic steatohepatitis (NASH). | ||
*Alcoholic liver disease, alcoholic steatohepatitis (ASH). | *[[Alcoholic liver disease]], alcoholic steatohepatitis (ASH). | ||
Periportal predominant (zone I) - ''TAPES'':<ref name=pcddx_steatosis/> | Periportal predominant (zone I) - ''TAPES'':<ref name=pcddx_steatosis/> | ||
*Total parenteral nutrition (TPN). | *Total parenteral nutrition (TPN). | ||
*[[AIDS]]. | *[[AIDS]]. | ||
*Phosphorus poisoning. | *[[Phosphorus poisoning]]. | ||
*Exogenous steroids. | *Exogenous steroids. | ||
*[[Starvation]].<ref name=pmid10600264>{{Cite journal | last1 = Nagy | first1 = I. | last2 = Németh | first2 = J. | last3 = Lászik | first3 = Z. | title = Effect of L-aminocarnitine, an inhibitor of mitochondrial fatty acid oxidation, on the exocrine pancreas and liver in fasted rats. | journal = Pharmacol Res | volume = 41 | issue = 1 | pages = 9-17 | month = Jan | year = 2000 | doi = 10.1006/phrs.1999.0565 | PMID = 10600264 }}</ref> | *[[Starvation]].<ref name=pmid10600264>{{Cite journal | last1 = Nagy | first1 = I. | last2 = Németh | first2 = J. | last3 = Lászik | first3 = Z. | title = Effect of L-aminocarnitine, an inhibitor of mitochondrial fatty acid oxidation, on the exocrine pancreas and liver in fasted rats. | journal = Pharmacol Res | volume = 41 | issue = 1 | pages = 9-17 | month = Jan | year = 2000 | doi = 10.1006/phrs.1999.0565 | PMID = 10600264 }}</ref> | ||
| Line 108: | Line 108: | ||
<gallery> | <gallery> | ||
Image:Periportal_hepatosteatosis_intermed_mag.jpg | Periportal steatosis. (WC/Nephron) | Image:Periportal_hepatosteatosis_intermed_mag.jpg | Periportal steatosis. (WC/Nephron) | ||
Image:Non-alcoholic_fatty_liver_disease1.jpg | Centrilobular steatosis. (WC/Nephron) | Image:Non-alcoholic_fatty_liver_disease1.jpg | Centrilobular steatosis. (WC/Nephron) | ||
</gallery> | </gallery> | ||